Oncopeptides AB Stock: price and insider trades · Sweden

This page follows insider dealings at Oncopeptides AB as filed with Finansinspektionen, a company from the Health Care sector based in Stockholm, Sweden. The group dates from 2000. Over the twelve months to 30 October 2026, 16 filings were filed, from 9 insiders.

No insider sold shares on the market over the period. Instead, the filings list 5 purchases totalling €4,255, made by 2 insiders. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 2 board members. Biggest ticket of the year: €2,210, bought by Christine Elizabeth Rankin and made public on 18 March 2026 (0.0038% of market cap).

For context, the typical company on the same exchange (median of 1,035 companies) published 9 filings over the same period, against 16 filings here. Looking back to 2017, when coverage begins, insiders filed 117 purchases and 15 sales.

Within a 30-day window, 1 purchase overlapped with buying by a second insider. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 18 March 2026, 235 days ago. Half of the filings or more reach the Finansinspektionen feed on the day of the trade. Under the Market Abuse Regulation, managers have three business days to notify their trades.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.